-
Disparities in Access to Gene Therapy in the European Union: Ethical and Regulatory Challenges
Sep 9, 2025, 16:22 PM -
Real-World Data for External Controls: Insights From EMA Regulatory Submissions
Sep 9, 2025, 16:22 PM -
Clinical Characteristics Among Patients Screening for Hepatitis C Virus (HCV) and HCV Positivity Rates, 2020-2024: Analysis of US Real-World Data
Sep 9, 2025, 16:22 PM -
Revisiting Rarity: Would Yesterday’s NICE Highly Specialized Technologies Still Qualify Today?
Sep 9, 2025, 16:22 PM -
Synthetic Data Generation Methods Using Artificial Intelligence (AI): A Simple New AI Tool That Generates Synthetic Data Using Generative Adversarial Network (CTGAN), Copula GANs, and Sequential Decision Tree Methods
Sep 9, 2025, 16:22 PM -
Evaluating the Value Elements Considered in Health Technology Assessments of Paroxysmal Nocturnal Hemoglobinuria Treatments: A Targeted Review
Sep 9, 2025, 16:22 PM -
Real-World Insights Into Prostate Cancer Management Using Electronic Health Record-Derived Data From the UK
Sep 9, 2025, 16:22 PM -
Use of Multilevel Network Meta Regression (ML-NMR) Model in RET Mutation-Positive Medullary Thyroid Cancer (MTC)
Sep 9, 2025, 16:22 PM -
Evaluating the Annual Cost of Progression in CD30+ Cutaneous T-cell Lymphomas Following 2L+ Systemic Treatment in Italy
Sep 9, 2025, 16:22 PM -
Economic and Clinical Impact of Advanced Therapies in Moderate-to-Severe Rheumatoid Arthritis in Spain: CIARA Study
Sep 9, 2025, 16:22 PM -
Caregiver QALYs Deserve Better: Why It's Time for a Methodological Rethink
Sep 9, 2025, 16:22 PM -
The Greek Drug Price Negotiation Committee and Its Contribution in Optimizing the Management of EOPYY's Pharmaceutical Budget
Sep 9, 2025, 16:22 PM -
Feasibility of Indication-Specific Pricing for Life Cycle Management of an Innovative Rare Disease Product
Sep 9, 2025, 16:22 PM -
Value of the France Early Access Pathways: Highlighting Benefits for Patients and Industry Sponsors of the Novel Therapeutic Fosmanogepix Addressing High Unmet Clinical Needs in Invasive Fungal Infections
Sep 9, 2025, 16:22 PM -
Readying for the Second Wave: What, When, and How Must Orphan Medicine Manufacturers Prepare for EU HTAR?
Sep 9, 2025, 16:22 PM -
Challenges at the Interface Between EUHTA (JCA) and National HTA in Germany (AMNOG): Expected Limitations to Synergy Effects and Implications for AMNOG Dossier Preparation
Sep 9, 2025, 16:22 PM -
Advancing the Science of Qualitative Patient Preference Assessment Using Large Language Models
Sep 9, 2025, 16:22 PM -
Addressing Clinical Uncertainties in ATMP Reimbursement: A Review of European Methodological Guidelines and Practices
Sep 9, 2025, 16:22 PM -
Development and Validation of a Machine Learning Model for Predicting French HAS ASMR Ratings Using Product and Disease Characteristics
Sep 9, 2025, 16:22 PM -
Melatonin Use Among Children and Adolescents: A Finnish Nationwide Drug Utilization Study
Sep 9, 2025, 16:22 PM
